Chapter 1061 The Cost Is Priceless

In the third batch of quotations, there are many top pharmaceutical companies and even many individuals.

Many of these pharmaceutical companies have already obtained the exclusive agency rights for the first and second rounds of auctions, but they have not stopped competing for exclusive agency rights in other regions.

For a company like Ito Group, 2.5 billion US dollars have been spent, do you still care about 100 million US dollars?

As long as you win the exclusive agency rights in a certain area, it means you can get a batch of generic cancer drugs.

After getting the universal medicine for cancer, who knows where this batch of universal medicine for cancer is used?

Would Xingchen Pharma not know about this loophole?

Of course I know, but Xingchen Pharmaceutical did not stop them from doing so. They competed with each other, and it was Xingchen Pharmaceutical who ultimately benefited. Why not earn money?

For those top group companies competing for the third batch, as long as they win the exclusive agency rights in a certain region, their own costs will be reduced a lot.

This kind of change is almost all on the facade, and anyone can take part.

The third batch is also the last batch. Although the number is large, the competition is also quite fierce.

At the last minute, auction prices in various countries almost doubled, and the lowest price has exceeded 200 million US dollars.

In the last minute, the bidding numbers rolled wildly, and it was almost impossible to see what the price was.

No one knows what the final transaction price will be.

Even those top groups can't assert that they will be able to win the exclusive agency rights in a certain region.

If there is more, it feels a little unworthy, and if there is less, it is a little uncomfortable to be robbed.

Ding.

The price of the third batch of transactions was freshly released.

Everyone was stunned by the price in front of them.

The highest in a country, reaching 635 million US dollars.

To know that the price of the second round is a little less than $500 million, and the $635 million is more than $100 million more than the price of the second round, you can see the crazy behavior of these investors.

The difference between the second and third rounds of exclusivity is the supply of generic cancer drugs.

The annual supply of the first round of generic cancer drugs was 1,200 copies.

The annual supply of the second round of generic cancer drugs is 600 copies.

Only 300 copies of the third round of generic cancer drugs are left in a year's supply.

Divide the cost of the exclusive agency fee equally among each cancer generic drug, and the price doubles.

However, there are not many more than 500 million US dollars in the third round, most of which are around 300 million US dollars.

The lowest one was only $265 million.

The auction of three rounds of exclusive agency rights came to a successful conclusion.

This auction lasted for three hours, but the turnover exceeded 100 billion US dollars.

The hot spot about the auction of cancer generic drugs has been firmly occupying the list of major entertainment platforms.

"Xingchen Pharmaceutical is too profitable, right? A small exclusive agency, the income exceeds 100 billion US dollars, plus the general cancer drug sold to them, the income is afraid to exceed 200 billion US dollars, right? I know, it was a shock, an auction directly created a Fortune 500 company."

"Xingchen Pharmaceutical can make so much money, I am not jealous. This is a solution to a terminal illness that has plagued human history for many years. It is absolutely deserved to be able to obtain this benefit."

"I don't object to Xingchen Pharmaceutical's making so much money. It's just that these exclusive agency fees are so expensive that it will cost more than three million US dollars to be divided equally among each general cancer drug?"

"More than that, according to the published information, the average price of a generic cancer drug in Sam's country is nearly four million US dollars. I am afraid that few people can afford it."

"We ordinary people should not worry about this. Even if they find out in their conscience that it drops to one million dollars, the people who can't be cured still can't be cured, but for those rich people, it is equivalent to giving them hope of life. ."

"It would be great if Xingchen Pharmaceutical lowered the price to the same level as Huaxia, so that most people can afford it."

"Fuck, the reason why Huaxia people can buy a copy with 200,000 yuan is because of the benefits that Xingchen Pharma gave to Huaxia people. Is it true that Xingchen Pharma doesn't need to make money? I don't know how much Xingchen Pharma has invested in research and development. funds.

However, from the investment of large companies such as Pfizer Pharmaceuticals and Ito Pharmaceuticals in the research and development of tumor treatment drugs, the investment of Xingchen Pharmaceuticals can probably be estimated.

The cost of new drug development for Pfizer is about $950 million on average.

The research and development cost of new drugs of Ito Pharmaceutical is about 1.1 billion US dollars on average.

The above listed are all world-renowned pharmaceutical companies. The average cost of each of their new drugs is as high as one billion US dollars. It is only with their high-end technology that this cost can be reduced.

Look at the R&D costs of other pharmaceutical companies, most of which are as high as $1.5 billion, or even $2 billion.

The cost of research and development of drugs is terribly high. This is the research and development of ordinary drugs. For an epoch-making product such as a general drug for cancer treatment, the investment of Xingchen Pharmaceutical in it may not be less than 10 billion US dollars, or even more.

Xingchen Pharma spent so much cost to develop a universal drug for cancer treatment. Why do you think that the price will be reduced when the price is reduced? "

When this netizen replied, he also published the research and development costs of the world's well-known pharmaceutical companies on the Internet. He didn't know who this person was, but he had such a great ability to obtain these materials.

In the information uploaded by this netizen, it is not a simple cost introduction, but more of the internal cost of the pharmaceutical company.

Generally speaking, such documents related to the cost of medicines are absolutely confidential documents, and it is impossible for ordinary people to take them out.

Most of the people on the Internet are melon eaters. When they saw the information listed by this netizen, they subconsciously believed it.

Thinking about the forced live broadcast of the incident not long ago, it is not so surprising.

For them, cancer is very close and far away, it is better to eat melons to feel more comfortable.

In his spare time, Liu Mingyu will also visit major entertainment platforms, swiping Douyin, swiping Star Assistant and so on.

After seeing a series of analysis by this netizen, Liu Mingyu couldn't help but give him a thumbs up, the analysis was too right.

If cancer generic drugs are really researched from scratch, let alone ten billion dollars, I am afraid that adding zero will not be enough.

Don't you see, since cancer appeared in human society in the last century, major pharmaceutical companies have spent more than 100 billion US dollars to develop corresponding special drugs.

Five hundred billion dollars, not even one trillion dollars.

However, the research and development cost of cancer generic drugs is much lower than this netizen's analysis.

Well, of course, this has to remove the cost of energy spar. After all, energy spar has no price, and no one knows how much it should be calculated.

If you count the energy spar, the cost is priceless.